100% Quality Guarantee
PhD-Level Technical Support
Riltovetbart Antibody - SDS-PAGE
Key Features

Riltovetbart Antibody (GXBS01398)

SKU GXBS01398
Product Type Research Grade Biosimilar
Antibody Type Monoclonal
Host Species Canine
Reactivity Canine
Applications ELISA, FACS, Functional assay, Research in vivo
Isotype IgG2-kappa
$677 - $2,208

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Riltovetbart Antibody

Riltovetbart Antibody is a research-grade biosimilar monoclonal antibody targeting IL-31. It is a caninized IgG2-kappa antibody. Reactivity: Canine. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.

Tirnovetmab (KIND-016) is an antibody. Tirnovetmab can be used for experiment research. • The IL-4, IL-13 and IL-31 pathways in atopic dermatitis., PMID:34106037 • IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis., PMID:37831760 • Interleukin-31: The "itchy" cytokine in inflammation and therapy., PMID:33629401 • A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1., PMID:24373353 • Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis., PMID:38117036 • Nemolizumab: First Approval., PMID:35834124 • Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis., PMID:35842249 • The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching., PMID:32673566 • Pruritus as a Distinctive Feature of Type 2 Inflammation., PMID:33807098 • Targeting Interleukin-31 in Prurigo., PMID:37888922

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose